跳至主要内容
临床试验/CTIS2023-503209-13-00
CTIS2023-503209-13-00进行中(未招募)1 期

Co-administration of Acetaminophen with Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants – The ACEDUCT Trial

Royal College Of Surgeons In Ireland0 个研究点目标入组 310 人开始时间: 2023年4月5日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
310

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 17(—)
性别
All

入选标准

  • 1.Preterm infants born <27+0 weeks gestational age admitted to one of four study NICUs: Mount Sinai Hospital, Sunnybrook Health Sciences Centre, McMaster Children’s Hospital, or the Rotunda Hospital, 2.Permission given by the attending clinician to approach and then consent obtained from parents, 3.Diagnosis of PDA = 1.5 mm on echocardiography with unrestrictive predominantly left to right shunt, 4.Designated to receive first treatment course with intravenous or enteral ibuprofen, as decided by the attending team.

排除标准

  • 1.Chromosomal anomaly, 10.Cases of severe hepatocellular insufficiency., 2.Pre-treatment renal dysfunction defined as urine output < 1ml/kg/hour for the previous 24 hours or serum creatinine > 100 micromol/L, 3.Pre-treatment hepatic dysfunction defined as serum aminotransferase (ALT) > 100 units/L94, 4.Platelet count <50,000 per microliter and no plan to transfuse platelets, 5.Permission denied by the attending clinician to approach parents, 6.Parental consent not available, 7.Previous exposure to PDA medical treatment with any drug (prophylactic indomethacin use for prevention of intraventricular hemorrhage will not be considered as PDA treatment)., 8.Use of any other investigational medicinal product within previous 30 days, 9.Any other medical condition/or treatment that contraindicates treatment with paracetamol or ibuprofen, such ashypersensitivity to paracetamol, propacetamol hydrochloride, or to any of the excipients listed in Section 6.1 of the SmPC for Paracetamol 10mg/ml solution for infusion

研究者

相似试验